BLOOD CANCER 201: MOVING BEYOND THE BASICS OF DISEASE, TREATMENT, AND THE ROLE OF THE HCP

November 10, 2021






Treatment guidelines are constantly evolving. For the most current treatment guidelines, please refer to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) at: https://www.nccn.org/guidelines/category_1. NCCN makes no warranties of any kind whatsoever regarding their


content, use or application and disclaims any responsibility for their application or use in any way.


At the time of this presentation, there were treatments noted to be in trials and pending FDA approval that may have since been FDA approved. A list of FDA approved treatments to treat blood cancers can be accessed at: <u>https://www.LLS.org/Drugs</u>.




























WHAT ARE THE DIFFERENCES IN GENETICS & GENOMICS

Genetics (YOU)	Genomics (YOUR TUMOR/CANCER)
Genetics can help identify your risk of developing cancer	Genomics can help guide your treatment once you have cancer
Genetic testing detects hereditary (from your parents) alterations in DNA that can be passed from one generation to the next through genes	Genomic testing detects acquired (over the course of your life) alterations in DNA; 90% of cancer is acquired
Harmful variants in some genes are known to be associated with an increased risk of developing cancer (contributes to about 5-10% of all cancers) (NIH, 2019)	Once you have cancer, the activity and interaction of certain genes in your tumor tissue influences the behavior of your tumor, including how likely it is to grow or spread
Once you know your genetic risk for cancer, you can take steps to lower that risk (i.e., lifestyle changes)	Once you have the personalized information from the genomic testing, you and your doctor can decide what treatment you need
ANCER IS IN OUR BLOOD. https://www.genome.gov/about-genomics/fact-sheets/Genetics-vs-Genomics	



IMMUNOHISTOCHEMISTRY (IHC)






This image was originally published in ASH Image Bank. Mir Alikhan, MD. Classical Hodgkin lymphoma - IHC. ASH Image Bank. 2021; #00063753. © the American Society of Hematology

BEATING CANCER IS IN OUR BLOOD.


13


۵

FLOW CYTOMETRY



https://cellcartoons.net







This image was originally published in ASH Image Bank. Girish Venkataraman, MD, MBBS; John Kennedy Sidney Sir Philip, MD; Sandeep Gurbuxani, MD, PhD. BPDCN-Flow. ASH Image Bank. 2018; #00061729. © the American Society of Hematology.




LEUKEMIA & LYMPHOMA SOCIETY°


BEATING CANCER IS IN OUR BLOOD.

























<section-header><section-header><section-header><section-header><list-item><list-item><list-item><list-item><list-item>





CASE STUDY # 1

- 57-year-old female, employed with employer group insurance
- Chronic Myeloid Leukemia (CML) diagnosis
- Was hospitalized and needs to begin treatment right away
- Wondering about getting a second opinion
- Insurance coverage issues- medication initially denied
- Concerns about coping with chronic nature of CML



BEATING CANCER IS IN OUR BLOOD.

LEUKEMIA & LYMPHOMA SOCIETY°



HOW DO I CHOOSE A TREATMENT CENTER, BLOOD CANCER SPECIALIST, OR GET A SECOND OPINION?


Questions to ask:


- Is care at the treatment center covered by my insurance plan?
- Does my primary care doctor or hematology-oncologist have confidence in this treatment center?
- What type of accreditation does the treatment center have? Do the treatment center and staff have experience treating my specific type of blood cancer?
- Does the center offer the most current treatments available?
- Does the center participate in clinical trials (research studies) related to my diagnosis?
- Are adequate support staff (nurses, social workers, case managers, patient advocates) available?
- Will I see the same support staff members at each visit?
- Is there a pharmacy on the premises or nearby?
- If a stem cell transplant is part of the treatment plan, is this center experienced in performing the type of stem cell transplant I will need?
- Can I speak to other cancer patients who are being treated or were treated at this center?


BEATING CANCER IS IN OUR BLOOD.

LEUKEMIA & LYMPHOMA

SOCIETY







۵

PRECISION MEDICINE

Biomarkers Significant for Study and Treatment of Hematologic Cancers


Chromosome and Gene Abbreviations	Associated Cancer	Treatment Correlation	
Philadelphia chromosome t(9;22) (translocation between chromosomes 9+22)	Chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL)	Responds to imatinib (Gleevec®), dasatinib (Sprycel®), nilotinib (Tasigna®)	
IDH2 (R140 or R172)	Acute myeloid leukemia (AML)	Responds to enasidenib (Idhifa®)	
JAK2 V617F	Myeloproliferative neoplasms (MPNs): polycythemia vera (PV), myelofibrosis (MF), essential thrombocythemia (ET)"	Responds to ruxolitinib (Jakafi*)	
PML-RARA	Acute promyelocytic leukemia (APL)	Responds to all- <i>trans</i> retinoic acid (ATRA), arsenic trioxide (Trisenox [®])	
FLT3-ITD	Acute myeloid leukemia (AML)	Responds to midostaurin (Rydapt [®])	
ALK rearrangement	Anaplastic large-cell lymphoma (ALCL)	Responds to crizotinib (Xalkori®)*	
BRAF V600E	Hairy cell leukemia	Responds to vemurafenib (Zelboraf [®])*	


*This drug is not FDA approved for this indication


**Use of ruxolitinib for this diagnosis has not been FDA approved.

Table 1. This table lists some of the biomarkers that are currently known to be significant for the study and treatment of hematologic cancers.


BEATING CANCER IS IN OUR BLOOD.




















UNDERSTANDING COSTS ASSOCIATED WITH CLINICAL TRIALS

Medicare or Medicaid)	
Standard of care tests and treatment.	Co-pays, deductibles, out-of- network costs
Cost of complications of treatment.	 Travel or lodging for patient and/or caregiver.
May or may not cover phase 1 trials.	Food and other incidentals.
 May or may not cover trials that take place of out-of-network or out of state. 	Loss of employment income for patient and/or caregiver
	Child care, pet boarding and home maintenance costs.
	 treatment. Cost of complications of treatment. May or may not cover phase 1 trials. May or may not cover trials that take place of out-of-network or


CASE STUDY #2 37-year-old female working presently, but needs a stem cell transplant and will be • losing her job and healthcare coverage Acute Lymphoblastic Leukemia (ALL) diagnosis Single mother **Financial concerns** . Insurance concerns • Support resources • Childcare concerns I FUKEMIA & LYMPHOMA SOCIETY° BEATING CANCER IS IN OUR BLOOD.



KEY POINTS TO LEAVE WITH:

- All cancer is genetic, but genetic changes are mostly acquired through your lifetime, few are inherited
- Patients and caregivers benefit from being connected with support and resources prior to diagnosis, throughout treatment, and into survivorship
- Biomarker testing is ESSENTIAL to accurate, complete and thorough diagnosis
- Each patient and caregiver has a unique lived experience and the care we provide should be tailored to their needs - physical, emotional, financial, psychosocial, cultural.
- Precision medicine is changing the way we treat blood cancer.

BEATING CANCER IS IN OUR BLOOD.



43

BLOOD CANCER 201: MOVING BEYOND THE BASICS OF DISEASE, TREATMENT, AND THE ROLE OF THE HCP

Resources for HCPs

- □ Free CME & CE courses: <u>www.LLS.org/CE</u>
- □ Fact Sheets for HCPs: <u>www.LLS.org/CE</u>
- Podcast series for HCPs: <u>www.LLS.org/CE</u>
- □ HCP Patient Referral Form: <u>www.LLS.org/HCPreferral</u>
- LLS Other Helpful Organizations: <u>www.LLS.org/OHO</u>

Clinical Trials and Research

- Clinical Trials: Learn more about clinical trials: www.LLS.org/ClinicalTrials
- Cartery Research: Focused on finding cures and driving research: www.LLS.org/Research



BEATING CANCER IS IN OUR BLOOD.

LEUKEMIA & LYMPHOMA SOCIETY°

